Patents Assigned to Juno Therapeutics GmbH
  • Publication number: 20240101613
    Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, and compositions thereof and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells such as a population of lymphocytes. In some aspects, the disclosure provides methods and reagents for the stimulation, e.g.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 28, 2024
    Applicant: Juno Therapeutics GmbH
    Inventors: Thomas SCHMIDT, Christian STEMBERGER, Tom KOWSKI, Ken PRENTICE
  • Patent number: 11913024
    Abstract: Provided herein are methods for culturing cells, including stimulating or expanding (proliferating), a plurality of cells in a composition of cells such as a population of lymphocytes. In some aspects, provided methods and reagents for the culturing, such as stimulation or expansion (proliferation), of cell populations involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for expansion or proliferation or other stimulation of a population of cells, and then such stimulatory agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: February 27, 2024
    Assignee: Juno Therapeutics GmbH
    Inventors: Lothar Germeroth, Christian Stemberger, Patricia Gräf
  • Patent number: 11866465
    Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion, activation, and/or survival, of a composition of cells such as a population of lymphocytes.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 9, 2024
    Assignee: Juno Therapeutics GmbH
    Inventors: Thomas Schmidt, Christian Stemberger, Tom Kowski, Ken Prentice
  • Publication number: 20230295567
    Abstract: Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes. In some aspects, provided are methods and reagents for the stimulation, e.g., of expansion (proliferation), survival or persistence, activation, costimulation, or other effect, of cell populations that involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are reagents containing a plurality of binding sites for agents, such as multimerization reagents, and thus the one or more agents are multimerized by reversibly binding to the reagent, e.g., thereby creating a stimulatory reagent (multimerized agent), having stimulatory agents multimerized thereon.
    Type: Application
    Filed: October 7, 2022
    Publication date: September 21, 2023
    Applicant: Juno Therapeutics GmbH
    Inventors: Lothar Germeroth, Christian Stemberger, Patricia Graf, Keenan Bashour
  • Publication number: 20230190952
    Abstract: Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates. In some embodiments, the cell surface molecule does not contain an intracellular signaling domain or is not capable of mediating intracellular signaling. In some embodiments, the cells engineered to contain the cell surface conjugate, such as T cells, further contain a genetically engineered recombinant receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). Also provided are methods of detecting, identifying, selecting or targeting cells expressing the cell surface conjugates, such as in connection with methods of manufacturing engineered cells or in connection with administration of such cells to subjects, including methods of adoptive cell therapy.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 22, 2023
    Applicant: Juno Therapeutics GmbH
    Inventors: Lothar GERMEROTH, Christian STEMBERGER
  • Patent number: 11517627
    Abstract: Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates. In some embodiments, the cell surface molecule does not contain an intracellular signaling domain or is not capable of mediating intracellular signaling. In some embodiments, the cells engineered to contain the cell surface conjugate, such as T cells, further contain a genetically engineered recombinant receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). Also provided are methods of detecting, identifying, selecting or targeting cells expressing the cell surface conjugates, such as in connection with methods of manufacturing engineered cells or in connection with administration of such cells to subjects, including methods of adoptive cell therapy.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: December 6, 2022
    Assignee: Juno Therapeutics GmbH
    Inventors: Lothar Germeroth, Christian Stemberger
  • Patent number: 11466253
    Abstract: Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes. In some aspects, provided are methods and reagents for the stimulation, e.g., of expansion (proliferation), survival or persistence, activation, costimulation, or other effect, of cell populations that involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are reagents containing a plurality of binding sites for agents, such as multimerization reagents, and thus the one or more agents are multimerized by reversibly binding to the reagent, e.g., thereby creating a stimulatory reagent (multimerized agent), having stimulatory agents multimerized thereon.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: October 11, 2022
    Assignee: Juno Therapeutics GmbH
    Inventors: Lothar Germeroth, Christian Stemberger, Patricia Gräf, Keenan Bashour
  • Publication number: 20220243223
    Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.
    Type: Application
    Filed: January 18, 2022
    Publication date: August 4, 2022
    Applicant: Juno Therapeutics GmbH
    Inventors: Keenan BASHOUR, Semih U. TAREEN
  • Publication number: 20220229054
    Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.
    Type: Application
    Filed: March 29, 2022
    Publication date: July 21, 2022
    Applicants: TECHNISCHE UNIVERSITAET MUENCHEN, JUNO THERAPEUTICS GMBH
    Inventors: Magdalena NAUERTH, Dirk BUSCH, Lothar GERMEROTH
  • Publication number: 20220195388
    Abstract: The present invention relates to in vitro-methods of expanding a population of cells such as lymphocytes, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 23, 2022
    Applicant: Juno Therapeutics GmbH
    Inventors: Lothar Germeroth, Christian Stemberger
  • Patent number: 11320431
    Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: May 3, 2022
    Assignees: TECHNISCHE UNIVERSITAET MUENCHEN, JUNO THERAPEUTICS GMBH
    Inventors: Magdalena Nauerth, Dirk Busch, Lothar Germeroth
  • Patent number: 11274278
    Abstract: The present invention relates to in vitro-methods of expanding a population of cells such as lymphocytes, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: March 15, 2022
    Assignee: Juno Therapeutics GmbH
    Inventors: Lothar Germeroth, Christian Stemberger
  • Patent number: 11248238
    Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: February 15, 2022
    Assignee: Juno Therapeutics GmbH
    Inventors: Keenan Bashour, Semih U. Tareen
  • Publication number: 20220002669
    Abstract: Provided herein are methods for selecting and stimulating a plurality of cells in a sample of cells using column chromatography, and collecting the cells without using additional steps or reagents to facilitate detachment of the cells from the column. In some aspects, the methods provided herein reduce the time needed to generate a population of selected and stimulated cells useful for genetic engineering, and ultimately, cell therapy, compared to existing methods. Also provided are articles of manufacture and apparatus thereof.
    Type: Application
    Filed: October 30, 2019
    Publication date: January 6, 2022
    Applicant: Juno Therapeutics GmbH
    Inventors: Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Thomas SCHMIDT
  • Publication number: 20210032297
    Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion, activation, and/or survival, of a composition of cells such as a population of lymphocytes.
    Type: Application
    Filed: April 27, 2018
    Publication date: February 4, 2021
    Applicant: Juno Therapeutics GmbH
    Inventors: Thomas SCHMIDT, Christian STEMBERGER, Tom KOWSKI, Ken PRENTICE
  • Publication number: 20200316218
    Abstract: Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates. In some embodiments, the cell surface molecule does not contain an intracellular signaling domain or is not capable of mediating intracellular signaling. In some embodiments, the cells engineered to contain the cell surface conjugate, such as T cells, further contain a genetically engineered recombinant receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). Also provided are methods of detecting, identifying, selecting or targeting cells expressing the cell surface conjugates, such as in connection with methods of manufacturing engineered cells or in connection with administration of such cells to subjects, including methods of adoptive cell therapy.
    Type: Application
    Filed: January 19, 2018
    Publication date: October 8, 2020
    Applicant: Juno Therapeutics GmbH
    Inventors: Lothar GERMEROTH, Christian STEMBERGER
  • Publication number: 20200017880
    Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.
    Type: Application
    Filed: October 20, 2016
    Publication date: January 16, 2020
    Applicant: Juno Therapeutics GmbH
    Inventors: Keenan BASHOUR, Semih U. TAREEN
  • Publication number: 20190234844
    Abstract: The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 1, 2019
    Applicant: Juno Therapeutics GmbH
    Inventor: Herbert STADLER
  • Publication number: 20190227061
    Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.
    Type: Application
    Filed: June 27, 2017
    Publication date: July 25, 2019
    Applicants: TECHNISCHE UNIVERSITAET MUENCHEN, JUNO THERAPEUTICS GMBH
    Inventors: Magdalena NAUERTH, Dirk BUSCH, Lothar GERMEROTH
  • Publication number: 20190226951
    Abstract: The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 25, 2019
    Applicant: Juno Therapeutics GmbH
    Inventor: Herbert STADLER